Document is current

Article History

First Online: 8 October 2020

Declarations

:

: No sources of funding were used to conduct this study or prepare this manuscript.

: Michiko Tomiyasu, Kunihiko Hayashi, Yukio Moritsugu, Narihisa Miyachi, Kazuya Iwamoto, Masahiro Nitta, Masahiko Mori, and Kouji Iwasaki have no conflicts of interest that are directly relevant to the content of this article. All authors are members of the Japanese Association of Pharmaceutical Medicine. Kunihiko Hayashi is a salaried employee of Kyowa Kirin Co., Ltd. Tokyo, Japan. Yukio Moritsugu is a salaried employee of Merck & Co., Inc., Kenilworth, NJ, USA. Narihisa Miyachi is a salaried employee of PharmaEssentia Japan K.K. Kazuya Iwamoto is a salaried employee of Covance Inc., Princeton, NJ, USA. Masahiro Nitta is a salaried employee of Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan. Masahiko Mori is a salaried employee of Eisai Co., Ltd., Tokyo, Japan. Koji Iwasaki is a visiting professor of the Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors contributed to the conception, analysis, and interpretation of the manuscript, based on the MSL recommendation report by the task force team at the JAPhMed. The authors prepared the draft and revised and approved all of its contents. The corresponding author undertook most of the revisions arising from peer review, which were subsequently approved by all authors. The authors agree to be accountable for all aspects of this publication.